Recruitment and inclusion procedures as & ldquo;pain killers & rdquo; in clinical trials?
ConclusionHemiplegic spontaneous cervical EDH occurs very rarely. It is often misdiagnosed as ischemic stroke and is likely to be administered with thrombolytic agents, making the patient's symptoms worse. Early diagnosis and rapid management of cervical EDH increase the likelihood of complete recovery of the patient's symptoms. Therefore, if there are unilateral weakness and neck pain without cranial nerve dysfunction and there is no evidence of stroke in the brain imaging, spinal EDH should be considered.
We describe the case of a 37-year-old man with a 20-year history of psoriatic arthritis. The patient presented with abdominal pain, watery diarrhea with mild hematochezia, and a reported 24-pound unintentional weight loss over the past five months. Of note, the patient began treatment with etanercept five months earlier after discontinuation of infliximab for his psoriatic arthritis symptoms. Colonoscopy with terminal ileum intubation revealed active colitis and intestinal biopsy results showed marked ulcerations and non-caseating granulomas, indicative of CD. Etanercept was subsequently discontinued and the patient was st...
Authors: Alexis AF, Rendon M, Silverberg JI, Pariser DM, Lockshin B, Griffiths CE, Weisman J, Wollenberg A, Chen Z, Davis JD, Li M, Eckert L, Gadkari A, Shumel B, Rossi AB, Graham NM, Ardeleanu M Abstract Dupilumab, a monoclonal antibody that blocks the shared receptor subunit for interleukin (IL)-4 and IL-13, is currently approved for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD). The efficacy and safety of dupilumab for AD among racial subgroups is unknown. This post hoc analysis from three phase 3 trials assessed the efficacy and safety of dupilumab vs placebo by ...
Authors: Green LJ, Yamauchi PS, Kircik LH Abstract Psoriasis (PsO) is a common, systemic, chronic inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling, and is associated with substantial physical, psychosocial, and economic health burdens. Currently, there is no cure for PsO; however, the introduction of biologic therapies has revolutionized the clinical management of patients with PsO by expanding treatment options to include multiple therapies with different mechanisms of action targeting cytokines, including tumor necrosis factor inhibitors (TNFis), interleukin (IL)-1...
ConclusionDifferent from current algorithms, our technique focuses on a particular problem in the field of speech pathology detection (SPD), not yet explored in detail, proposing a way to successfully solve it. Furthermore, the results we obtained stimulate broaden studies involving speech data inconsistencies whilst providing a valid contribution.
Anyone else using these ALTO guidelines for non opioid pain management in your ED? We have a non opioid pain policy with big banners in the ED informing patients and although physicians are technically free to order whatever they think is appropriate, we get emails with the names of physicians who are the biggest offenders with ordering narcotics in the ER so there is definitely pressure to not order them if you can help it. FMD is 100% behind the push for no opioids. At first, I was really... ALTO....sounds like a muppet character
Condition: Postoperative Pain Interventions: Drug: Piroxicam group; Drug: Placebo Sponsor: Ain Shams University Recruiting
Conditions: Pain, Acute; Preterm Infant; Breast Milk Interventions: Other: Olfactive stimulation intervention with familiarization; Other: Olfactive stimulation intervention; Other: Standard care Sponsor: St. Justine's Hospital Not yet recruiting
Conditions: Substance Use Disorders; Pain Intervention: Behavioral: SBIRT-PM Sponsors: Yale University; National Center for Complementary and Integrative Health (NCCIH); National Institute on Drug Abuse (NIDA); US Department of Veterans Affairs Not yet recruiting
Conditions: Anesthesia; Pain Interventions: Drug: Dexmedetomidine; Drug: Propofol; Drug: Fentanyl; Device: Peripheral Nerve Stimulation; Drug: Placebo Sponsor: Keith M. Vogt, MD, PhD Not yet recruiting